Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis

Table 1 Descriptive characteristics of study cohort

Characteristic
Total number of patients analyzed	29
Female, N (%)	7 (24.1)
Median age (y) at diagnosis with EoE (IQR)	13.2 (6.4)
Median age (y) at study enrollment (IQR)	14.1 (4.6)
Features of GC therapy
Duration of GC therapy (days ± SD)	104.6 ± 23.7
Oral viscous budesonide, N (%)	26 (89.7)
Swallowed fluticasone, N (%)	3 (10.3)
Concomitant conditions, N (%)
Asthma	21 (72.4)
Allergies^a	27 (93.1)
Eczema	10 (34.5)
Additional forms of GC therapy, by patient, N (%)
Total number of patients receiving additional forms	13 (44.8 %)
Inhaled corticosteroids^b	11 (37.9 %)
Intranasal	1 (3.4 %)
Topical	2 (6.9 %)

EoE eosinophilic esophagitis, ICS inhaled corticosteroids, IQR interquartile range, GC glucocorticoid, N number, SD standard deviation, y years
^aA diagnosis of allergy was made based on skin prick testing for food and/or environmental allergies by an allergist
^bMost participants had a history of infrequent ICS use during inter-current infection only. Two participants were being actively treated with daily moderate ICS doses (Flovent 250 mcg daily and Alvesco 400 mcg daily)

ISSN: 1710-1492